Literature DB >> 34021316

Does the cardioprotective effect of Empagliflozin involve inhibition of the sodium-proton exchanger?

Elizabeth Murphy1, David A Eisner2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34021316      PMCID： PMC8848318          DOI： 10.1093/cvr/cvab137

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  10 in total

1.  How does endothelin-1 cause a sustained increase in intracellular sodium and calcium which lead to hypertrophy?

Authors:  Elizabeth Murphy; David A Eisner
Journal:  J Mol Cell Cardiol       Date:  2006-10-04       Impact factor: 5.000

Review 2.  Intracellular pH regulation in heart.

Authors:  Richard D Vaughan-Jones; Kenneth W Spitzer; Pawel Swietach
Journal:  J Mol Cell Cardiol       Date:  2008-11-08       Impact factor: 5.000

3.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

4.  Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.

Authors:  Laween Uthman; Rianne Nederlof; Otto Eerbeek; Antonius Baartscheer; Cees Schumacher; Ninée Buchholtz; Markus W Hollmann; Ruben Coronel; Nina C Weber; Coert J Zuurbier
Journal:  Cardiovasc Res       Date:  2019-08-01       Impact factor: 10.787

5.  Empagliflozin inhibits Na+ /H+ exchanger activity in human atrial cardiomyocytes.

Authors:  Maximilian Trum; Johannes Riechel; Simon Lebek; Steffen Pabel; Samuel T Sossalla; Stephan Hirt; Michael Arzt; Lars S Maier; Stefan Wagner
Journal:  ESC Heart Fail       Date:  2020-09-18

Review 6.  H⁺-activated Na⁺ influx in the ventricular myocyte couples Ca²⁺-signalling to intracellular pH.

Authors:  Carolina D Garciarena; Jae Boum Youm; Pawel Swietach; Richard D Vaughan-Jones
Journal:  J Mol Cell Cardiol       Date:  2013-04-18       Impact factor: 5.000

7.  Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.

Authors:  Antonius Baartscheer; Cees A Schumacher; Rob C I Wüst; Jan W T Fiolet; Ger J M Stienen; Ruben Coronel; Coert J Zuurbier
Journal:  Diabetologia       Date:  2016-10-17       Impact factor: 10.122

8.  Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.

Authors:  Laween Uthman; Antonius Baartscheer; Boris Bleijlevens; Cees A Schumacher; Jan W T Fiolet; Anneke Koeman; Milena Jancev; Markus W Hollmann; Nina C Weber; Ruben Coronel; Coert J Zuurbier
Journal:  Diabetologia       Date:  2017-12-02       Impact factor: 10.122

9.  Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.

Authors:  Yu Jin Chung; Kyung Chan Park; Sergiy Tokar; Thomas R Eykyn; William Fuller; Davor Pavlovic; Pawel Swietach; Michael J Shattock
Journal:  Cardiovasc Res       Date:  2021-12-17       Impact factor: 10.787

10.  Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions.

Authors:  Coert J Zuurbier; Antonius Baartscheer; Cees A Schumacher; Jan W T Fiolet; Ruben Coronel
Journal:  Cardiovasc Res       Date:  2021-12-17       Impact factor: 10.787
  10 in total
  1 in total

1.  SGLT2 inhibitors and the cardiac Na+/H+ exchanger-1: the plot thickens.

Authors:  Yu Jin Chung; Kyung Chan Park; Sergiy Tokar; Thomas R Eykyn; William Fuller; Davor Pavlovic; Pawel Swietach; Michael J Shattock
Journal:  Cardiovasc Res       Date:  2021-12-17       Impact factor: 10.787
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.